Literature DB >> 6108780

Comparative pharmacodynamics and plasma levels of beta-adrenoceptor blocking drugs.

R Gugler, R Krist, H Raczinski, K Höffgen, G Bodem.   

Abstract

1. Metoprolol (ME), pindolol (PI) and propranolol (PR) were studied in nine subjects at different doses and at 'maximum beta-adrenoceptor blockade' at a defined exercise load. Exercise tests were performed after each dosing period; isoprenaline stimulation was studied at the highest dose level. 2. ME and PR reduced heart rate at rest with most doses tested, while PI had no effect on resting heart rate. 3. Exercise heart rate was reduced with the smallest daily doses (ME 75 mg; PI 7.5 mg; PR 60 mg), and maximum reduction was from 163 to 116 beats/min (ME), 124 (PT) and 115 (PR) beats/min with daily doses of 242, 23 and 233 mg, respectively. 4. Resting blood pressure was not significantly affected by any beta-adrenoceptor blocker dose, but exercise induced blood pressure decreased from 166 to 130 (ME), 138 (PI) and 131 (PR) mm Hg, respectively. 5. Mean plasma concentrations at 'maximum beta-adrenoceptor blockade' were 158 (ME), 24 (PI) and 159 (PR) ng/ml without significant differences in the plasma level variation between beta-adrenoceptor blockers. 6. Isoprenaline doses required to increase heart rate by 30 beats/min were 3.8 microgram (control), 22 microgram (ME), 458 microgram (PI) and 200 microgram (PR), respectively. The differences may be due to different ratios of beta 1, beta 2 activity of the beta-adrenoceptor blockers tested.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6108780      PMCID: PMC1430092          DOI: 10.1111/j.1365-2125.1980.tb01769.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  The effect of pindolol on exercise-induced cardiac acceleration in relation to plasma levels in man.

Authors:  R Gugler; W Höbel; G Bodem; H J Dengler
Journal:  Clin Pharmacol Ther       Date:  1975-02       Impact factor: 6.875

2.  A sensitive gas chromatographic method for the determination of propranolol in human plasma.

Authors:  E Di Salle; K M Baker; S R Bareggi; W D Watkins; C A Chidsey; A Frigerio; P L Morselli
Journal:  J Chromatogr       Date:  1973-09-26

3.  Comparison of the effects of I.C.I. 50172 and propranolol on the cardiovascular responses to adrenaline, isoprenaline and exercise.

Authors:  I Brick; K J Hutchison; D G McDevitt; I C Roddie; R G Shanks
Journal:  Br J Pharmacol       Date:  1968-09       Impact factor: 8.739

4.  Intravenously administered isoproterenol sulfate dose-response curves in man.

Authors:  C F George; M E Conolly; T Fenyvesi; R Briant; C T Dollery
Journal:  Arch Intern Med       Date:  1972-09

Review 5.  The use of beta-adrenergic receptor blocking drugs in dysrhythmias.

Authors:  D Gibson; E Sowton
Journal:  Prog Cardiovasc Dis       Date:  1969-07       Impact factor: 8.194

Review 6.  Activation and blockade of beta adrenoceptors in common cardiac disorders.

Authors:  J W Black; B N Prichard
Journal:  Br Med Bull       Date:  1973-05       Impact factor: 4.291

Review 7.  Beta-adrenergic receptor blocking drugs in hypertension.

Authors:  F O Simpson
Journal:  Drugs       Date:  1974       Impact factor: 9.546

8.  Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment.

Authors:  C Bengtsson; G Johnsson; C G Regårdh
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

9.  A method for the fluorimetric determination of 4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB46), a beta-blocking agent, in plasma and urine.

Authors:  W L Pacha
Journal:  Experientia       Date:  1969-08-15

10.  Pharmacodynamic studies of beta adrenergic antagonism induced in man by propranolol and practolol.

Authors:  G Bodem; H L Brammell; J V Weil; C A Chidsey
Journal:  J Clin Invest       Date:  1973-04       Impact factor: 14.808

View more
  12 in total

1.  Pharmacokinetic-pharmacodynamic modelling of oxprenolol in man using continuous non-invasive blood pressure monitoring.

Authors:  R Koopmans; B Oosterhuis; J M Karemaker; J Wemer; C J van Boxtel
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Human pharmacokinetic and pharmacodynamic studies on Ro31-1118, a new beta-adrenoceptor antagonist.

Authors:  P C O'Connor; J M Arnold; A N Brown; R J Francis; M B Finch; D B Galloway; D W Harron; D G McDevitt; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1985-03       Impact factor: 4.335

3.  The effect of hydralazine on steady-state plasma concentrations of metoprolol in pregnant hypertensive women.

Authors:  S Lindeberg; B Holm; P Lundborg; C G Regårdh; B Sandström
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Cardiac beta 2-adrenoceptors and the inotropic response to exercise in man.

Authors:  C Nyarko-Adomfeh
Journal:  Clin Auton Res       Date:  1991-12       Impact factor: 4.435

5.  Chronic propranolol administration during pregnancy. Maternal pharmacokinetics.

Authors:  M T Smith; I Livingstone; M J Eadie; W D Hooper; E J Triggs
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man.

Authors:  A Wellstein; D Palm; H F Pitschner; G G Belz
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  Comparison of the haemodynamic effects of bucindolol, propranolol and pindolol in healthy volunteers.

Authors:  P C O'Connor; M J Finch; D W Harron; P A Meredith; D G McDevitt; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

8.  Metoprolol in acute myocardial infarction. A pharmacokinetic and pharmacodynamic study.

Authors:  P H Held; C G Regårdh
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  Comparative haemodynamic dose-response effects of intravenous propranolol and pindolol in patients with coronary heart disease.

Authors:  B Silke; G I Nelson; R C Ahuja; R C Okoli; S H Taylor
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

10.  Observations on the mechanism underlying the differences in exercise and isoprenaline tachycardia after cardioselective and non-selective beta-adrenoceptor antagonists.

Authors:  D McGibney; W Singleton; B Silke; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.